Literature DB >> 27628078

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Francis X McCormack, Nishant Gupta, Geraldine R Finlay, Lisa R Young, Angelo M Taveira-DaSilva, Connie G Glasgow, Wendy K Steagall, Simon R Johnson, Steven A Sahn, Jay H Ryu, Charlie Strange, Kuniaki Seyama, Eugene J Sullivan, Robert M Kotloff, Gregory P Downey, Jeffrey T Chapman, MeiLan K Han, Jeanine M D'Armiento, Yoshikazu Inoue, Elizabeth P Henske, John J Bissler, Thomas V Colby, Brent W Kinder, Kathryn A Wikenheiser-Brokamp, Kevin K Brown, Jean F Cordier, Cristopher Meyer, Vincent Cottin, Jan L Brozek, Karen Smith, Kevin C Wilson, Joel Moss.   

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM.
METHODS: Systematic reviews were performed to summarize evidence pertinent to our questions. The evidence was summarized and discussed by a multidisciplinary panel. Evidence-based recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
RESULTS: After considering the panel's confidence in the estimated effects, the balance of desirable (i.e., benefits) and undesirable (i.e., harms and burdens) consequences of treatment, patient values and preferences, cost, and feasibility, recommendations were formulated for or against specific interventions. These included recommendations for sirolimus treatment and vascular endothelial growth factor D testing and recommendations against doxycycline and hormonal therapy.
CONCLUSIONS: Evidence-based recommendations for the diagnosis and treatment of patients with LAM are provided. Frequent reassessment and updating will be needed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27628078      PMCID: PMC5803656          DOI: 10.1164/rccm.201607-1384ST

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  113 in total

1.  Lymphangiopericytoma; case report of a previously undescribed tumor type.

Authors:  H T ENTERLINE; B ROBERTS
Journal:  Cancer       Date:  1955 May-Jun       Impact factor: 6.860

2.  Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.

Authors:  Marsha A Moses; Jay Harper; Judah Folkman
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade.

Authors:  Suzana Pinheiro Pimenta; Bruno Guedes Baldi; Milena Marques Pagliarelli Acencio; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2011 Jul-Aug       Impact factor: 2.624

4.  Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis.

Authors:  Kameswara Rao Badri; Ling Gao; Elizabeth Hyjek; Noa Schuger; Lucia Schuger; Wei Qin; Yvonne Chekaluk; David J Kwiatkowski; Xiaoning Zhe
Journal:  Am J Respir Crit Care Med       Date:  2013-03-15       Impact factor: 21.405

5.  [A case of pulmonary lymphangiomyomatosis diagnosed by TBLB and treated with progesterone and oophorectomy].

Authors:  H Kuwabara; S Biyazima; T Osaka; F Yasuhara; Y Chizimatsu; K Inatomi; M Washizaki; H Homma; S Saeki; A Yamanaka
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1984-09

6.  Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex.

Authors:  Mario Schiavina; Valerio Di Scioscio; Paola Contini; Alberto Cavazza; Andrea Fabiani; Marco Barberis; Alessandro Bini; Annalisa Altimari; Robin M T Cooke; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  Am J Respir Crit Care Med       Date:  2007-04-12       Impact factor: 21.405

7.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

8.  Pulmonary lymphangiomyomatosis.

Authors:  W Dishner; E M Cordasco; J Blackburn; S Demeter; H Levin; W D Carey
Journal:  Chest       Date:  1984-06       Impact factor: 9.410

9.  Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis.

Authors:  Claire M Ellender; Trevor J Williams; Julian Gooi; Gregory I Snell; Helen M Whitford
Journal:  Respirol Case Rep       Date:  2015-05-18

10.  Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.

Authors:  Darcy A Krueger; Hope Northrup
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

View more
  76 in total

1.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.

Authors:  Alexandre Franco Amaral; Martina Rodrigues de Oliveira; Olívia Meira Dias; Fábio Eiji Arimura; Carolina Salim Gonçalves Freitas; Milena Marques Pagliarelli Acencio; Vanessa Adélia de Alvarenga; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  Lung       Date:  2019-01-08       Impact factor: 2.584

2.  Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.

Authors:  Souheil El-Chemaly; Angelo Taveira-Dasilva; Hilary J Goldberg; Elizabeth Peters; Mary Haughey; Don Bienfang; Amanda M Jones; Patricia Julien-Williams; Ye Cui; Julian A Villalba; Shefali Bagwe; Rie Maurer; Ivan O Rosas; Joel Moss; Elizabeth P Henske
Journal:  Chest       Date:  2017-02-10       Impact factor: 9.410

Review 3.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

4.  A Comparative Analysis of Pulmonary and Critical Care Medicine Guideline Development Methodologies.

Authors:  Noah C Schoenberg; Alan F Barker; John Bernardo; Robin R Deterding; Jerrold J Ellner; Dean R Hess; Neil R MacIntyre; Fernando J Martinez; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

Review 5.  Summary for Clinicians: Lymphangioleiomyomatosis Diagnosis and Management Clinical Practice Guideline.

Authors:  Laura C Feemster; Patrick G Lyons; Rohini S Chatterjee; Pranav Kidambi; Francis X McCormack; Joel Moss; Kevin C Wilson; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2017-07

Review 6.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

Review 7.  Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Authors:  Vera P Krymskaya; Francis X McCormack
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

Review 8.  The Genetics of Pneumothorax.

Authors:  Philip M Boone; Rachel M Scott; Stefan J Marciniak; Elizabeth P Henske; Benjamin A Raby
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

9.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 10.  Interstitial lung disease: the diagnostic role of bronchoscopy.

Authors:  Jad Kebbe; Tony Abdo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.